<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The incidence of secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are rarely reported in an homogeneous patient population treated for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) </plain></SENT>
<SENT sid="1" pm="."><plain>Less than 10 per cent of <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> are usually observed in patients treated for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> and NHL </plain></SENT>
<SENT sid="2" pm="."><plain>Data on the incidence of <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> induced by modern chemotherapeutic regimens is needed </plain></SENT>
<SENT sid="3" pm="."><plain>Between January 1985 and January 1989, 20 patients with localized gastric non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (stage I to IIE) were prospectively treated at the Institut Gustave-Roussy with PROMACE-MOPP multi-agent chemotherapy and involved-field irradiation </plain></SENT>
<SENT sid="4" pm="."><plain>The mean age was 54 years (range 23 to 69 years) </plain></SENT>
<SENT sid="5" pm="."><plain>Seven patients died while on therapy or relapsed 2 to 28 months after therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Thirteen patients were followed up for at least 5 years </plain></SENT>
<SENT sid="7" pm="."><plain>Three of the 13 long-term survivors (23 per cent) developed a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) 48, 62 and 72 months after the end of therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Cytogenetic analysis was performed in two cases and showed-7 and 18q- in one case, t(9;21)(q13;q22), 21q+, i17q in the other case </plain></SENT>
<SENT sid="9" pm="."><plain>PROMACE-MOPP plus radiotherapy should not be recommended in patients with localized gastric non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> due to the high risk of developing secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
</text></document>